Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs PEMFEXY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in nucleotide synthesis, leading to disruption of DNA and RNA synthesis.
Mild to moderate pain,Fever
Mesothelioma: In combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.,Non-small cell lung cancer: First-line treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in combination with pembrolizumab and platinum chemotherapy.,Non-small cell lung cancer: Maintenance therapy for patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.,Non-small cell lung cancer: Treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
500 mg/m2 intravenously over 10 minutes on day 1 of a 21-day cycle, in combination with cisplatin.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Terminal elimination half-life ~17 hours (range 13-26 hours) in patients with normal renal function; prolonged to >24 hours in renal impairment. Supports every-21-day dosing.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Pemetrexed is primarily excreted unchanged in the urine; limited hepatic metabolism occurs via unspecified pathways. It is not significantly metabolized by CYP450 enzymes.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Renal excretion (70-90% unchanged drug), biliary/fecal (<5%)
Approximately 10-20% bound to serum albumin; extensive tissue binding.
~95% bound to plasma proteins (primarily albumin)
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Vd ~16 L/m² (approximately 0.4 L/kg); distributes into total body water with extensive tissue binding.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
IV only; no oral bioavailability due to poor absorption and extensive first-pass metabolism.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Cr Cl 45-59 m L/min: reduce dose to 400 mg/m2; Cr Cl 30-44 m L/min: reduce dose to 250 mg/m2; Cr Cl <30 m L/min: do not administer.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
No dosage adjustment required for Child-Pugh class A or B. For Child-Pugh class C, reduce dose by 50%.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Safety and efficacy not established in pediatric patients; not recommended.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
No dose adjustment based on age alone; monitor renal function and adjust according to Cr Cl.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
PEMFEXY can cause fetal harm when administered to a pregnant woman. Pemetrexed is contraindicated in patients who are pregnant or may become pregnant. Women of childbearing potential should be advised to avoid becoming pregnant during treatment with PEMFEXY.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Myelosuppression: Pemetrexed can cause severe bone marrow suppression, including neutropenia, thrombocytopenia, and anemia. Monitor blood counts and adjust doses accordingly.,Renal toxicity: Pemetrexed is primarily eliminated renally; reduce dose in patients with creatinine clearance <45 m L/min. Not recommended for patients with Cr Cl <30 m L/min.,Cutaneous reactions: Severe dermatologic reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported; discontinue if severe.,Gastrointestinal toxicity: Diarrhea, nausea, and vomiting are common; administer premedication with corticosteroids and folic acid/vitamin B12 to reduce toxicity.,Pneumonitis: Interstitial pneumonitis has been reported; monitor for respiratory symptoms and discontinue if confirmed.,Radiation recall: Increased risk of radiation recall reactions in patients who have received prior radiotherapy.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Pregnancy: Pemetrexed can cause fetal harm; contraindicated in pregnant women.,Severe hypersensitivity: History of severe hypersensitivity reaction to pemetrexed or any excipient.,Concomitant yellow fever vaccine: Increased risk of systemic vaccine reaction.,Breastfeeding: Discontinue nursing during treatment due to potential harm to the infant.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
No known food interactions. However, avoid grapefruit juice if taking concurrent CYP3A4 substrates due to potential enzyme inhibition? Not applicable for PEMFEXY. No dietary restrictions required.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Category D: Positive evidence of human fetal risk. Avoid in pregnancy unless no safer alternative. First trimester: high risk of neural tube defects, craniofacial and limb malformations, growth restriction. Second/third trimester: increased risk of preterm delivery, low birth weight, fetal myelosuppression.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Excreted in human milk. M/P ratio unknown. Potential for serious adverse reactions in nursing infants, including myelosuppression. Advise discontinue breastfeeding or the drug, considering importance to mother.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Pregnancy-induced increases in plasma volume and renal clearance may decrease pemetrexed exposure. No formal dose recommendations; consider therapeutic drug monitoring if available. Use with folic acid and vitamin B12 supplementation to reduce toxicity.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
PEMFEXY (pembrolizumab) is a humanized monoclonal antibody that targets PD-1. Clinical pearls: 1) Administer as IV infusion over 30 minutes; do not shake vial. 2) Monitor for immune-mediated adverse reactions such as pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis. 3) Corticosteroids may be used to manage severe immune-related adverse events. 4) Do not coadminister with systemic immunosuppressants unless managing toxicity. 5) No dose adjustment required for renal or mild hepatic impairment. 6) Check PD-L1 expression for NSCLC appropriateness.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Inform your healthcare provider about any history of autoimmune disease, organ transplant, or lung problems.,Report new or worsening symptoms such as cough, chest pain, shortness of breath, diarrhea, abdominal pain, blood in stool, jaundice, severe fatigue, weight changes, or skin rash.,Do not receive live vaccines during treatment.,Avoid pregnancy while on treatment; use effective contraception.,Report signs of infusion reaction such as fever, chills, flushing, or hypotension during and after infusion.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs PEMFEXY, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. PEMFEXY is a Antineoplastic Antifolate that works by Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in nucleotide synthesis, leading to disruption of DNA and RNA synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and PEMFEXY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of PEMFEXY is: 500 mg/m2 intravenously over 10 minutes on day 1 of a 21-day cycle, in combination with cisplatin.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and PEMFEXY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. PEMFEXY is classified as Category C. Category D: Positive evidence of human fetal risk. Avoid in pregnancy unless no safer alternative. First trimester: high risk of neural tube defects, craniofacial and limb malforma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.